News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Investment is additive to KKR’s existing health care growth strategy
The company is confident of addressing all the observations within the stipulated time
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
hey were educated about the 7- step hand-washing technique trainings
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Subscribe To Our Newsletter & Stay Updated
